Sponsored by Cerexa, Inc.

Phase	Quota	Distance
Phase 4		Near

This is a study of safety and effectiveness of ceftaroline fosamil in children with Complicated Community-acquired Pneumonia receiving antibiotic therapy in the hospital.

Study Start Date: October 2012

Estimated Completion Date: August 2014

Specialties: Pediatrics: Clinical Pharmacology,Pediatric Pulmonology,Peds Infectious Disease Infectious Disease: Antimicrobials,Peds Infectious Disease,Pulm/Thoracic Infections Pulmonology: Clinical Pharmacology,Peds Pulmonology,Pulm/Thoracic Infections Pharmacy: Antimicrobials,Drug Trials Hospitalist:

Interventions

• Drug: Ceftaroline fosamil
• Drug: IV Ceftriaxone and Vancomycin

Inclusion criteria

• Presence of CABP warranting 3 days of initial hospitalization
• Confirmed presence of indicators of complicated CABP

Exclusion criteria

• Hypersensitivity or allergic reaction to vancomycin or any β-lactam antimicrobial
• Confirmed or suspected infection with a pathogen known to be resistant to IV study drugs or known infection at baseline with a sole atypical organism
• Confirmed or suspected respiratory tract infection attributable to sources other than community acquired bacterial pneumonia
• Non-infectious causes of pulmonary infiltrates

Study Locations And Contact Information

• Investigational Site, Long Beach California